Table 2.
Pooled adverse outcome data
| Outcome | Studies reporting | Events stem cell treatment | Events control | Odds ratio | 95% CI | P-value |
|---|---|---|---|---|---|---|
| Death | ||||||
| 3–6 months | 9 | 9/556 | 6/455 | 1.25 | 0.49–3.14 | 0.64 |
| 12–18 months | 3 | 2/142 | 7/148 | 0.33 | 0.08–1.40 | 0.13 |
| Cardiac death | ||||||
| 3–6 months | 2 | 4/102 | 3/99 | 1.30 | 0.28–5.95 | 0.74 |
| Reinfarction | ||||||
| 3–6 months | 9 | 11/595 | 15/491 | 0.61 | 0.30–1.25 | 0.17 |
| 12–18 months | 2 | 2/131 | 5/134 | 0.68 | 0.01–39.75 | 0.85 |
| HF hospitalization | ||||||
| 3–6 months | 7 | 6/396 | 9/375 | 0.69 | 0.27–1.79 | 0.45 |
| 12–18 months | 3 | 6/142 | 6/148 | 1.15 | 0.14–9.29 | 0.90 |
| Target-vessel revascularization | ||||||
| 3–6 months | 5 | 20/275 | 27/261 | 0.69 | 0.38–1.28 | 0.24 |
| 12–18 months | 2 | 16/112 | 24/117 | 0.62 | 0.31–1.25 | 0.18 |
| Stent thrombosis | ||||||
| 3–6 months | 4 | 5/214 | 5/216 | 0.98 | 0.29–3.26 | 0.97 |
| 12–18 months | 2 | 1/112 | 3/117 | 0.33 | 0.03–3.26 | 0.34 |
| Stroke | ||||||
| 3–6 months | 4 | 0/240 | 0/159 | – | – | – |
| Arrhythmia | ||||||
| 3–6 months | 2 | 6/153 | 6/152 | 0.99 | 0.31–3.15 | 0.99 |
| 12–18 months | 2 | 11/131 | 11/134 | 1.03 | 0.42–2.53 | 0.95 |
Abbreviations: CI, confidence interval; HF, rehospitalization for heart failure.